(Reuters) - Liver cancer treatment maker Sirtex Medical <SRX.AX> said on Monday that the U.S. Federal Trade Commission cleared its $1.4 billion buyout by a Chinese consortium, clearing a major hurdle for the deal to go through.
The company had agreed last month to be taken over by Beijing-based CDH Investments and its partner, China Grand Pharmaceutical and Healthcare Holdings <0512.HK>, which trumped a bid from U.S.-based Varian Medical Systems <VAR.N>.
Sirtex, which has a large portion of its operations in the United States, received clearance for the buyout from Australia's Foreign Investment Review Board earlier in the month.
(Reporting by Ambar Warrick in Bengaluru; Editing by Stephen Coates)
